Overview
BC95 is a clinician-led bowel cancer testing service designed to support structured assessment of colorectal cancer risk using complementary, evidence-based tests.
The services integrate stool-based screening and hereditary risk assessment to provide a broad clinical view than any single test alone.
BC95 is intended to support clinical decision-making and appropriate referrals, not to replace diagnostic investigation.
What is BC95?
BC95 brings together:
- Stool DNA methylation test (EarlyTect®)
- Hereditary cancer risk assessment using multi-gene germline testing
- Quantitative faecal immunochemical testing (qFIT)
By combining these approaches, BC95 supports assessment of:
- Current bowel cancer risk
- Occult bleeding
- Inherited predisposition
Availability through EDX Medical
BC95 is available in the UK through EDX Medical as an integrated testing service.
For ordering information, turnaround times, and pathway integration, please contact EDX Medical at moc.lacidemxde@ofni.
Tests included in BC95
EarlyTect® – Stool DNA Methylation test
EarlyTect® analyses abnormal methylation of SC2 gene in stool-derived DNA, a biomarker associated with colorectal cancer.
Hereditary Cancer Testing
Hereditary Cancer testing assess inherited genetic variants associated with colorectal and related cancer risk using multi-gene NGS panels, provided by BGI Genomics.
qFIT – Quantitative Immunochemical Test
qFit measures the concentration of human haemoglobin in stool and is widely used in colorectal cancer screening and triage pathways
